Welcome to the final frontier in your body.
By now you’ve probably heard of the far-reaching endocannabinoid system (ECS). Every human and animal (except for insects) has one. The ECS is comprised of several different types of receptors and enzymes, and is involved in cellular signaling throughout our organs and tissues.
While researchers have made progress, there’s still much to learn. Scientists are discovering new kinds of cannabinoid receptors every day. They’re also making new discoveries about the two most common types of ECS receptors – CB1 and CB2 – and how they are activated.
CB1 receptors primarily affect our nervous system, and are found in our brains, spinal cords, nerves, intestines, and connective tissues. When activated by a cannabinoid, CB1 receptors cause retrograde signaling in the following areas:
- Memory and Brain
- Digestion & Gut
- Immune System
- Joint and Connective Tissues
While CB1 receptors primarily work on the brain and nervous system, CB2 receptors are generally associated with the immune system. CB2 receptors are scattered throughout various parts of the body, including the spleen, tonsils, thymus, immune cells, monocytes, macrophages, and B and T cell lymphocytes. Studies about the activation of CB2 receptors and the potential effects on neurodegenerative, autoimmune, gastrointestinal, cardiovascular, and psychiatric diseases are underway. Additional research is being performed on the role CB2 receptors may play in inflammation, pain, and bone and skin health.
MendCBD+ has been specifically blended with cannabinoids and terpenes to activate your CB1, CB2, and other receptors. Carefully-chosen terpenes – including β-Caryophyllene, myrcene, like those in the coveted Harlequin strain – bind with CB2 receptors. MendCBD+ also includes food-grade essential oils like frankincense and turmeric, which have been shown to improve the activation of endocannabinoid receptors.
Begg M., et. al (2005) “Evidence for novel cannabinoid receptors”, Pharmacol. Therp.Vol. 106, Issue 2: 133-145. Retrieved October 10, 2019 from 10.1016/j.pharmthera.2004.11.005.
Zou, Shenglong and Kumar, Ujendra (2018, March 13) “Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.” Retrieved October 8, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877694/.
Russo, E. (2016, July 1) “Clinical Endocannabinoids Deficiency (CED): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome, and Other Treatment-Resistant Conditions?”, Cannabis Canninboid Res., Volume 1(1): 154-165. Retrieved November 5, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/.